Patients with diverse skin types can experience diagnostic delays, access to care issues, and quality-of-life burdens that a navigator program may be able to help alleviate.
Early results of a navigator program for underserved patients with skin of color demonstrated improved patient support and continuity of care.1 The results were shared at Fall Clinical Dermatology 2023.
Patients with diverse skin types often experience diagnostic delays because provider education focuses on how skin diseases present in lightly pigmented skin.2 Patients with skin of color also seem to experience a higher burden on quality of life.2 For psoriasis, the presentation in patients with skin of color may look like other diseases.3
In addition to diagnostic delays, patients of color in general have lower access to specialty care and specialty treatment.2 To address this, SUNY Downstate Health Sciences University created the Determi-Nation Patient Navigator Program, which pairs underserved patients with skin of color with medical students to serve as liaisons with the medical care team.
The program was launched in 2021 with 6 second-year students with the goal of preparing them to deliver equitable conscientious care as health care professionals.4 The navigators check in with patients who miss appointments, remind them to pick up prescriptions, and provide educational materials in multiple languages.
The poster presented at the conference shared the results for the first set of patients who were enrolled in the program.1 The median duration of patient participation in the program was approximately 4 months.
A total of 20 patients were enrolled; 18 were Black/African American and 2 were Afro-Caribbean. The majority were female (85%) and spoke English (80%). Three patients spoke Creole/French as their primary language and 1 patient spoke Spanish.
The most common dermatologic diagnosis was hidradenitis suppurativa (60%), followed by psoriasis and cutaneous lupus erythematosus (both 15%), stasis dermatitis (5%), and both hidradenitis suppurative and psoriasis (5%).
Patients had a total of 38 encounters, with the majority (63%) being by text and the majority (63%) being initiated by the navigator. The most common purpose for the encounter was scheduling an appointment (34%), followed by refilling prescriptions (26%).
The benefits of the program, according to the early results, were:
“While the program is still in its early stages, it demonstrates the potential value of tangible interactions between patients and dedicated navigators to improve patient support and continuity of care,” the researchers concluded.
References
1. Glick SA, Jakus J, Kabir S, et al. Addressing healthcare disparities and improving care for people with skin of color: preliminary results from the Determi-Nation SUNY Downstate student-based patient navigator project. Presented at: Fall Clinical Dermatology 2023; Las Vegas, Nevada; October 19-22, 2023. Poster 12.
2. Joszt L. Providers need to be educated about how conditions may vary in skin of color, says Dr Andrew Alexis. The American Journal of Managed Care® website. April 18, 2023. Accessed November 17, 2023. https://www.ajmc.com/view/providers-need-to-be-educated-about-how-conditions-may-vary-in-skin-of-color-says-dr-andrew-alexis
3. Klein HE, Steinzor P. Dr Mona Shahriari talks unique challenges in treating psoriasis in patients with skin of color. The American Journal of Managed Care website. November 4, 2023. Accessed November 17, 2023. https://www.ajmc.com/view/dr-mona-shahriari-talks-unique-challenges-in-treating-psoriasis-in-patients-with-skin-of-color
4. SUNY Downstate to launch patient navigator program in partnership with Brooklyn Free Clinic and Brooklyn Center for Health Disparities. News release. SUNY Downstate Health Sciences University. July 19, 2021. Accessed November 17, 2023. https://www.downstate.edu/news-events/news/2021/07-19-2021.html
Study Reveals Decline in Inpatient Dermatology Services and Urgent Need for Strategic Support
May 17th 2024A recent study found significant regional disparities and a decline in inpatient dermatology encounters and providers across the US from 2013 to 2019, highlighting the need for increased support and improved access to specialized dermatologic care.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Study Reveals Decline in Inpatient Dermatology Services and Urgent Need for Strategic Support
May 17th 2024A recent study found significant regional disparities and a decline in inpatient dermatology encounters and providers across the US from 2013 to 2019, highlighting the need for increased support and improved access to specialized dermatologic care.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
2 Commerce Drive
Cranbury, NJ 08512